个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共7条记录   Benefits and risks of antipsychotic polypharmacy - An evidence-based review of the literature [作者：Tranulis, C; Skalli, L; Lalonde, P; Nicole, L; Shp, E,期刊：Drug safety, 页码：7-20 , 文章类型： Review，,卷期：2008年31-1] Combination antipsychotic prescription is an increasingly common practice in clinical psychiatry. This clinical practice is at odds with clinical guidelines promoting antipsychotic monotherapy. Moreover, there has been i... Methods for causality assessment of adverse drug reactions - A systematic review [作者：Agbabiaka, TB; Savovic, J; Ernst, E,期刊：Drug safety, 页码：21-37 , 文章类型： Review，,卷期：2008年31-1] Numerous methods for causality assessment of adverse drug reactions (ADRs) have been published. The aim of this review is to provide an overview of these methods and discuss their strengths and weaknesses. We conducted e... Data resources for investigating drug exposure during pregnancy and associated outcomes - The General Practice Research Database (GPRD) as an alternative to pregnancy registries [作者：Charlton, RA; Cunnington, MC; de Vries, CS; Weil, JG,期刊：Drug safety, 页码：39-51 , 文章类型： Review，,卷期：2008年31-1] Pregnancy registries are the most commonly used data resource for the post-marketing surveillance of drug teratogenicity. However, the limited sample size and potential selection bias in these registries has led us to in... Orlistat-associated adverse effects and drug interactions - A critical review [作者：Filippatos, TD; Derdemezis, CS; Gazi, IF; Nakou, ES; Mikhailidis, DP; Elisaf, MS,期刊：Drug safety, 页码：53-65 , 文章类型： Review，,卷期：2008年31-1] Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be a... Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation [作者：Kubitza, D; Mueck, W; Becka, M,期刊：Drug safety, 页码：67-77 , 文章类型： Article，,卷期：2008年31-1] Background: Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. Unwanted pro-arrhythmic effects are a comm... Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia - A retrospective analysis of a double-blind trial and an open-label extension [作者：Oertel, W; Poewe, W; Wolters, E; De Deyn, PP; Emre, M; Kirsch, C; Hsu, C; Tekin, S; Lane, R,期刊：Drug safety, 页码：79-94 , 文章类型： Article，,卷期：2008年31-1] Background and aim: Rivastigmine is now widely approved for the treatment of mild to moderately severe dementia in Parkinson's disease (PDD). However, since anticholinergic drugs have a role in the management of tremor i... Intelligent risk communication - Can it be improved? [作者：Czarnecki, A,期刊：Drug safety, 页码：1-6 , 文章类型： Editorial Material，,卷期：2008年31-1] Every year, regulators and scientists from academia and industry invest considerable time and effort into drug development, the assessment of safety, and subsequent risk-benefit communication. The observation of everyday...